# Forward Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/forward-therapeutics

- Industry: Biotechnology
- Headquarters: Palm Beach, US
- Website: www.forward-tx.com
- Total disclosed funding: $50M
- Latest round: Series A (Oct 31, 2023)
- Investors on record: 3

## About

Established in 2022 and based in Florida, US, Forward Therapeutics, Inc. operates as a biotechnology company that offers clinical-stage gene therapy for patients with rare diseases. Toufike Kanouni (CEO) and Ewan Taylor (CSO) are the co-founders of the company. In October 2023, Forward Therapeutics, Inc. raised USD 50 million in Series A funding from BVF Partners, including RA Capital Management and OrbiMed Advisors.

The company specializes in the delivery of oral medications for chronic inflammatory disorders. The firm focuses on target selection based on verified immunological targets, discovering pathways that have the potential to influence patient outcomes. Forward Therapeutics also combines scientific knowledge with operational efficiencies to ensure drug development through integrated discovery and development.

The organization plans to use the October 2023 funding to advance the clinical development of its small-molecule immunology medications.

## Funding rounds

- Series A, Oct 31, 2023, $50M — OrbiMed Advisors, BVF Partners, RA Capital Management

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A